If you need an accessible version of this item please contact JSTOR User Support

Intergeneric Poliovirus Recombinants for the Treatment of Malignant Glioma

Matthias Gromeier, Sylvie Lachmann, Myrna R. Rosenfeld, Philip H. Gutin and Eckard Wimmer
Proceedings of the National Academy of Sciences of the United States of America
Vol. 97, No. 12 (Jun. 6, 2000), pp. 6803-6808
Stable URL: http://www.jstor.org/stable/122718
Page Count: 6
  • Download PDF
  • Cite this Item

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If you need an accessible version of this item please contact JSTOR User Support
Intergeneric Poliovirus Recombinants for the Treatment of Malignant Glioma
Preview not available

Abstract

Poliovirus neuropathogenicity depends on sequences within the 5′ nontranslated region of the virus. Exchange of the poliovirus internal ribosomal entry site with its counterpart from human rhinovirus type 2 resulted in attenuation of neurovirulence in primates. Despite deficient virus propagation in cells of neuronal origin, nonpathogenic polio recombinants retain excellent growth characteristics in cell lines derived from glial neoplasms. Susceptibility of malignant glioma cells to poliovirus may be mediated by expression of a poliovirus receptor, CD155, in glial neoplasms. Intergeneric polio recombinants with heterologous internal ribosomal entry site elements unfolded strong oncolytic potential against experimentally induced gliomas in athymic mice. Our observations suggest that highly attenuated poliovirus recombinants may have applicability as biotherapeutic antineoplastic agents.

Page Thumbnails

  • Thumbnail: Page 
6803
    6803
  • Thumbnail: Page 
6804
    6804
  • Thumbnail: Page 
6805
    6805
  • Thumbnail: Page 
6806
    6806
  • Thumbnail: Page 
6807
    6807
  • Thumbnail: Page 
6808
    6808